DexCom, Inc. (DexCom) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. The Company had received approval from the United States Food and Drug Administration (FDA) for its third generation system, the SEVEN PLUS, which is designed for up to seven days of continuous use. The SEVEN PLUS is indicated for use as an adjunctive device to complement, not replace, information obtained from standard home blood glucose monitoring devices. The enabling technologies for the Company's sensors include biomaterials, membrane systems, electrochemistry and low power microelectronics.
|Headquarters||6340 Sequence Drive|
SAN DIEGO, CA, United States 92121
|Independent Chairman of the Board||Jonathan Lord|
|President, Chief Operating Officer, Director||Kevin Sayer|
|Chief Executive Officer, Director||Terrance Gregg|
|Chief Financial Officer, Vice President||Jess Roper|
|Executive Vice President - Strategy and Corporate Development||Steven Pacelli|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||70.7M||Book Value||$1.11|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||13.7|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-46.80%|
*GAAP = prior to non-GAAP analyst adjusted earnings.